Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5106 - Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Renal Cell Cancer


Elena Verzoni


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


E. Verzoni1, L. De Cecco2, M. Dugo2, D. Rinchai3, D. Bedognetti3, P. Grassi1, R. Ratta1, A. Cova4, P. Squarcina4, V. Huber4, R. Montone5, M. Sorrentino5, G. Procopio1, L. Rivoltini4

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Functional Genomics Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 3 Sidra Medical And Research Center, Sidra Medical and Research Center, Doha/QA
  • 4 Immunotherapy Of Human Tumors, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 5 Trial Center, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milano/IT


Abstract 5106


The impact of tyrosine kinase inhibitors (TKIs) on tumor immunity of patients (pts) with metastatic renal cell carcinoma (mRCC) is largely unknown. We investigated the activity of pazopanib in counteracting tumor-induced immunosuppression and boosting adaptive immune response.


Sixteen mRCC pts receiving first-line pazopanib were prospectively analyzed at baseline, 3 and 6 months for blood Immune profiling by multicolor cytofluorimetry. Gene expression analysis was performed by Illumina HT12v4 BeadChip Arrays. Data were evaluated by t-test, enrichment analysis and deconvolution algorithms.


Pazopanib administration (800 mg per os/daily) was associated with a significant decrease of cell subsets involved in immunosuppression, including CD14+ monocytes, monocytic CD14+ HLA-DRneg myeloid derived suppressor cells (MDSC) and CD14+PDL-1+ cells. Similarly, low density CD15+ granulocytic MDSC and CD4+ CD25high Foxp3+ regulatory T cells were reduced by treatment. Concomitantly, a boost of antitumor effectors, such as activated T lymphocytes (identified as CD3+PD-1dim T cells) and cytotoxic CD3-CD16+CD56dim NK cells, was observed. Changes were more evident at 3 months and in pts achieving clinical benefit (69%), defined as the sum of partial response and stable disease at first restaging. Interestingly, a statistically significant increase of lymphocyte/monocyte ratio, as determined by routine blood test was also detected. Gene expression analysis confirmed the immunoregulatory effects of pazopanib. By comparing with those collected after 3 months after treatment start and pre-treatment samples, pathway-enrichment analysis revealed a coherent modulation of NK Granzyme A, IL8 signaling and other immune-related pathways. Similarly, using deconvolution algorithms, we observed an enrichment of NK and CD8+ T cell transcripts.


Pazopanib reshapes tumor immunity by reducing immunosuppressive cells (MDSC and Treg) and triggering T cells and NK effectors. These data provide a strong rationale for using Pazopanib both before an immunocheckpoints inhibitors and also in combination strategies based on the synergism between TKIs and immunotherapy.

Clinical trial identification

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori of Milan




E. Verzoni: Reports receiving fees for serving on advisory boards from Pfizer and Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.